Gilead's pill succeeds in mid-stage bowel disease trial

Impact · against what's priced in

Gilead's successful mid-stage trial for bowel disease provides a positive catalyst as the market currently discounts revenue upside from the near-term pipeline. This result supports the potential for total revenue growth to exceed the 6.6% CAGR currently embedded in the stock price.

GILD+0.20: Challenges what's priced in
The price assumes: Revenue upside from the near-term pipeline
The market is not currently paying for pipeline revenue upside; the success of this mid-stage trial for bowel disease provides a concrete path toward accelerating revenue growth above the 6.6% the price requires.
What GILD's price assumes · Sep 10

Gilead's pill succeeds in mid-stage bowel disease trial

biotech▲14%
healthcare
pharmaceuticals
GILD
bowel disease
clinical trials
gilead

Top 1 mover · tap to explore

Gilead's pill succeeds in mid-stage bowel disease trial

How each ticker is affected

First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication

Gilead's pill succeeds in mid-stage bowel disease trial

How each ticker is affected

First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication

Track these names every morning.

Oculis lýkur slembiröðun í PREDICT-1 skráningarrannsókninni á Licaminlimab við TNFR1-miðluðum augnþurrki

PureTech Announces Presentation of Phase 1b Results for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) and Acute Myeloid Leukemia (AML) at ESMO 2026

Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.

Viking Therapeutics Just Raised $575 Million. Here's What It Means for the Obesity Stock's Next Chapter.

Gilead's pill succeeds in mid-stage bowel disease trial

How each ticker is affected

Next reads from the same story arc

First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication

Gilead's pill succeeds in mid-stage bowel disease trial

How each ticker is affected

Next reads from the same story arc

First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication

Track these names every morning.

Oculis lýkur slembiröðun í PREDICT-1 skráningarrannsókninni á Licaminlimab við TNFR1-miðluðum augnþurrki

PureTech Announces Presentation of Phase 1b Results for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) and Acute Myeloid Leukemia (AML) at ESMO 2026

Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.

Viking Therapeutics Just Raised $575 Million. Here's What It Means for the Obesity Stock's Next Chapter.